Pharmaceutical Technology Europe - April 2010 - (Page 7)

The current and future market for SNPs Single nucleotide polymorphisms (SNPs) are responsible for more than 80% of the variations between individuals, and are present throughout most genes and other important sequences in the human body, which makes them ideal for tracking down correlations between genotype and phenotype. As such, SNP analysis has become very important in the development of personalised medicines. Compared with gene sequencing technology, SNP analysis offers a shortcut to genotyping analysis because SNPs are the most common mutations; if they are linked to a disease then you can predict the disease if you find the SNP. of the development-stage products a reality. What is desired is a wide range of test–drug combinations. Although there are tests in development, progress is not fast enough to meet expectations on new test–drug combinations. Some new specific tests will be successful and will be considered a ‘personalised medicine’, but the expectation that all care will become personalised is unlikely to be met. There are also question marks over the future growth of the SNP analysis market. During 2009, the market hit a bump in the road. It had been anticipated that genome-wide association studies would result in the discovery of many disease associations for common diseases, but this has not happened. The scientific community had been relying on the assumption that common diseases were caused by common variants, which would be elucidated with SNP chips containing variants at 5% frequency. In reality, however, studies will need to look at rare variances at around 1% frequency or less. These are now being added to the newest chips and are expected to trigger a surge in research projects. term, however, lower multiplexing products used in clinical trials will begin to drive more growth. Prices are expected to drop continuously, offsetting the growth from increased adoption, and future analysers will be fitted with chips that have rarer variants and, thus, will offer improved predictability. PTE Market predictions The market for SNP analysis products has experienced rapid changes and a burst in growth, and we expect this to continue in the near term. According to our analysis, the global market for SNP analysis technologies is expected to be worth approximately $1.3 billion in 2014, with around 50% of sales coming from the US, and driven principally by whole genome SNP analysis products in the near term. In the longer Based on a contribution by Bruce Carlson, Publisher at Kalorama Information, publisher of the report SNP Geneotyping and Analysis Markets. To read the full version of this article, go to www.pharmtech.com/kalorama www.kaloramainformation.com Challenges One of the main challenges over the next decade will be to make many 1 CONTENTS 9 THE HUMAN GENOME 2 INTRODUCTION 11 CANCER THERAPY UPDATE 5 MORE THAN SCIENCE NEEDED 14 MANUFACTURING CHALLENGES 7 FUTURE SNP MARKET 16 TOP TECHNOLOGIES http://www.pharmtech.com/kalorama http://www.kaloramainformation.com

Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - April 2010

Pharmaceutical Technology Europe - April 2010
Table of Contents
Why Personalised Medicine Business Models will Require Long-Term Strategies and Great Flexibility in Order to be Successful
Science Alone Will Not Lead to Better Medicines
The Current and Future Market for SNPs
The Hype, Hope and Reality of Pharmacogenetic Tests
Unraveling the Human Genome
Progress in Molecular Diagnostics
Personalising Cancer Therapy
T Cells for Patient-Specific Cancer Treatments
Future Research Strategies for Glucocorticoid Therapy
Overcoming Manufacturing and Financial Challenges of Personalised Cell Therapies
Public-Private Partnerships Prosper
Eight Latest Technologies Showcased

Pharmaceutical Technology Europe - April 2010